Advances in Molecular Perspectives of Tumor-Initiating Cells on Cancer Therapy

Licun Wu

Abstract


Cancer stem cells (CSCs) known as tumorigenic cells are biologically distinct from diverse subpopulations. Cancer cell heterogeneity readily leads to development of drug resistance and tolerance to treatment. CSC hypothesis has resulted in incredible impact on the understanding and insight into tumor biology. More importantly, advances in molecular perspectives have achieved in the recent decades although many aspects of this hypothesis remain speculative and are still evolving. CSC has been considered a new cellular target for anticancer drug discovery. Along with identification of different CSC markers such as CD133, CD24, CD44, CD90 and signaling pathways such as Wnt/β-catenin, hedgehog and so on, different kinds of therapeutic approaches have been developed to work on these molecular targets, resulting in selective inhibition of CSC functions including self-renewal and differentiation. Most recent studies demonstrated that CR1 expression in colon CSC can promote the stem cell clone formation, CCR7 promotes breast CSC growth, TP53 splice can enhance the pluripotency of CSC through the positive regulation of Sox2, Oct3/4 and Nanog and other key factors, to increase the potential risk of cancer recurrence, and an exciting finding is that carbon nanomaterials may be used as a CSC sniper. Selectively targeting CSC has shown promising perspectives and may open a new venue for the treatment of cancer.




Cell Mol Med Res. 2017;1(1):2-6
doi: https://doi.org/10.14740/cmmr10e

Keywords


Tumor initiating cell; Cancer stem cell; Biomarker; Molecular target; Cancer therapy

Full Text: HTML PDF
 
Home     |     Log In     |      About     |      Search     |      Current     |      Archives     |      Submit      |     Subscribe


 

     

Aims and Scope

Current Issues

Conflict of Interest

About Publisher

Editorial Board

Archives

Copyright

Company Profile

Editorial Office

Misconduct and Retraction

Permissions

Company Registration

Contact Us

Abstracting and Indexing

ICMJE

Ownership

Instructions to Authors

Access

Declaration of Helsinki

Contact Publisher

Submission Checklist

Reprints

Terms of Use

Company Address

Submit a Manuscript

Open Access Policy

Privacy Policy

Browse Journals

Publishing Fee

Publishing Policy

Disclaimer

Recent Highlights

Peer-Review Process

Publishing Quality

Code of Ethics

Advertising Policy

Manuscript Tracking

Advanced Search

For Librarians

Careers

Publishing Process

Publication Frequency

For Reviewers

Propose a New Journal

       
       

Cellular and Molecular Medicine Research, quarterly, ISSN 0000-0000 (print), 0000-0000 (online), published by Elmer Press Inc.     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.thecmmr.org   editorial contact: editor@thecmmr.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

DECLARATION: THIS JOURNAL SITE OUTLOOK IS DESIGNED BY THE PUBLISHER AND COPYRIGHT PROTECTED. DO NOT COPY!